Zenyatta adds Interconnected Reduced Graphene Oxide to its Albany Graphite Product Development Pipeline

Zenyatta Ventures Ltd. (TSXV: ZEN, “Zenyatta” or the “Company”) today announced that it has added Interconnected Reduced Graphene Oxide (IC-rGO) to its product development pipeline, working with its research partner Prof. Aicheng Chen from the University of Guelph, Ontario. IC-rGO is a three-dimensional nanomaterial with potential applications in the energy and environmental industries. While working at Lakehead University in late 2016, Prof. Chen and his team first developed the nanomaterial using graphite sourced from Zenyatta’s Albany deposit in Northern Ontario – a unique form of graphite ideally suited to produce graphene and graphene derivatives. Patents are pending on the new nanomaterial. Zenyatta, which changed its management team earlier this year, has announced a new direction as a company, and will focus in the future on exploring new applications for the high-quality graphene that can be produced from its unique Albany deposit. “Our goal is to become vertically integrated – from producing the graphene right through to the development of high-value applications for this extraordinary material,” said Dr. Francis Dubé, Zenyatta’s Co-CEO and Head of Business Development and Technology. “We will work with our research partners and other leading industrial partners to become an IP incubator where we will co-develop IP that has the potential to be a game changer across multiple industries. Dr. Chen’s work is representative of the exciting prospects for graphene in years to come.” “IC-rGO represents a new class of 3-D platform, which is promising for many graphene-related applications such as sensors, catalysts, supercapacitors, batteries, adsorbents, and filters,” said Dr. Chen. The fabricated IC-rGO exhibits a high capacitance with impressive charging and discharging stability due to its covalent interconnections and unique 3D superstructure. It is anticipated that the discovery could facilitate the research and development of new types of 3D hybrids and functional graphene nanocomposites. For more information about IC-rGO, read more in The Royal Society of Chemistry journal, ChemComm (Chemical Communications). “This invention has the potential to become a structural platform that can be functionalized for multiple applications leading to further innovation and IP for Zenyatta and its shareholders,” said Dr. Dubé. “We are very fortunate to have talented research partners like Dr. Chen, and we are grateful to him and his team for their world-leading work in the graphene space.”

About Dr. Chen

In 2015, Dr. Aicheng Chen, Professor of Chemistry and Canada Research Chair in Materials and Environmental Chemistry at Lakehead, was awarded a Natural Science and Engineering Research Council of Canada (‘NSERC’) Collaborative Research and Development (‘CRD’) grant. The two primary focuses of this NSERC CRD project are the characterization of Zenyatta’s graphite and the development of new materials for practical applications derived from it. Since the award of the grant, Dr. Chen and his research group have made significant advances in the development of new graphene-based nanomaterials from Albany Graphite. Prof. Chen and his team have also developed a novel one-pot synthesis of fluorine functionalized graphene oxide (F-GO) which was reported in a March 1, 2017 news release. A patent was filed for this invention and a paper describing the process in more detail was published in the Electrochemistry Communications journal. Since late 2017, Dr. Chen has been a Professor of Chemistry, and the Director of the Electrochemical Technology Centre at the University of Guelph. His research interests span the areas of electrochemistry, biosensors, green chemistry, materials science and nanotechnology. If you have any questions, please feel free to contact us at 1-705-618-0900, or email us at info@zenyatta.ca. Or Dr. Francis Dubé, Co-CEO & Head of Business Development and Technology Tel: +1 (289) 821-2820 Email: fdube@zenyatta.ca
  • Share

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

To find out more about Zentek Ltd., please visit our website at www.zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR profile at www.sedar.com.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

Tyler Dunn

Director, Marketing & Communications


Subscribe for Updates

Interested in recieving press releases directly to your inbox? Subscribe to Zentek's mailing list for all the latest news.